Equine chorionic gonadotropin improves the efficacy of a progestin-based fixed-time artificial insemination protocol in Nelore (Bos indicus) heifers.
A total of 177 Nelore heifers were examined by ultrasonography to determine the presence or absence of a corpus luteum (CL) and received a 3mg norgestomet ear implant plus 2mg of estradiol benzoate i.m. On Day 8, implants were removed and 150 microg of d-cloprostenol i.m. was administered. At the time of norgestomet implant removal, heifers with or without CL at the time of initiating treatment were assigned equally and by replicate to be treated with 0IU (n=87) or 400IU (n=90) eCG i.m. All heifers received 1mg of EB i.m. on Day 9 and were submitted to fixed-time artificial insemination (FTAI) 30-34h later. The addition of eCG increased the diameter of the largest follicle (LF) at FTAI (10.6+/-0.2mm vs. 9.5+/-0.2mm; P=0.003; mean+/-SEM), the final growth rate of the LF (1.14+/-0.1mm/day vs. 0.64+/-0.1mm/day; P=0.0009), ovulation rate [94.4% (85/90) vs. 73.6% (64/87); P=0.0006], the diameter of the CL at Day 15 (15.5+/-0.3mm vs. 13.8+/-0.3mm; P=0.0002), serum concentrations of progesterone 5 days after FTAI (6.6+/-1.0 ng/ml vs. 3.6+/-0.7ng/ml; P=0.0009), and pregnancy per AI [P/AI; 50.0% (45/90) vs. 36.8% (32/87); P=0.04]. The absence of a CL at the beginning of the treatment negatively influenced the P/AI [30.2% (16/53) vs. 49.2% (61/124); P=0.01]. Therefore, the presence of a CL (and/or onset of puberty) must be considered in setting up FTAI programs in heifers. In addition, eCG may be an important tool for the enhancement of follicular growth, ovulation, size and function of the subsequent CL, and pregnancy rates in progestin-based FTAI protocols in Bos indicus heifers.
Sá Filho
M F
MF
Departamento de Reprodução Animal, FMVZ-USP, Rua Prof. Orlando Marques de Paiva, 87, CEP 05508-000, São Paulo, SP, Brazil.
Torres-Júnior
J R S
JR
Penteado
L
L
Gimenes
L U
LU
Ferreira
R M
RM
Ayres
H
H
Castro E Paula
L A
LA
Sales
J N S
JN
Baruselli
P S
PS
D000818:Animals; D002417:Cattle; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D003008:Cloprostenol / Q000008:administration & dosage; D003338:Corpus Luteum / Q000000981:diagnostic imaging; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D004973:Estrus Synchronization; D005260:Female; D006736:Horses; D007315:Insemination, Artificial / Q000379:methods / Q000662:veterinary*; D008186:Luteolytic Agents; D006080:Ovarian Follicle / Q000033:anatomy & histology / Q000187:drug effects; D010060:Ovulation; D011247:Pregnancy; D011282:Pregnenediones / Q000008:administration & dosage; D011374:Progesterone / Q000097:blood; D013997:Time Factors; D014463:Ultrasonography
D006063:Chorionic Gonadotropin; D004343:Drug Implants; D008186:Luteolytic Agents; D011282:Pregnenediones; C074283:estradiol 3-benzoate; C100284:norgestomet; D003008:Cloprostenol; D011374:Progesterone; D004958:Estradiol